Tricyclic Antidepressants May Increase the Incidence of Non-Hodgkin Lymphoma(7/2/2008) Researchers from Denmark reported that patients who are long-term takers of tricyclic antidepressant medications have a 53% increased incidence of non-Hodgkin lymphoma (NHL). These data were also published in the July issue of Epidemiology.
Increasing Body Mass Associated with Increasing Cancer Incidence and Mortality(11/19/2007) Researchers affiliated with the UK Million Women Study have reported that increasing body mass index (BMI) is associated with an increased risk of 10 specific types of cancer out of 17 evaluated. The details of this study appeared in an early on-line publication on November 6, 2007 in the British Medical Journal.
Occupational Solvents May Increase Risk of Lymphoma(10/5/2006) Researchers from Italy have reported that occupational exposure to solvents such as benzene, xylene, and toluene may increase the risk of developing non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL).
Fruits and Vegetables May Drastically Decrease Risk of Non-Hodgkin’s Lymphoma(6/27/2006) Researchers from Italy have reported that a high intake of fruits and vegetables may significantly decrease the risk of developing non-Hodgkin’s lymphoma (NHL). The details of this study appeared in the June 1, 2006, issue of the International Journal of Cancer .
Statins May Decrease Risk of Lymphoma(6/16/2006) Researchers from the Czech Republic, France, Germany, Ireland, Italy, and Spain have reported that individuals who regularly use statins may have a decreased risk of developing lymphoma. The details of this study appeared in the May 2006 issue of Cancer Epidemiology Biomarkers and Prevention.
Rituxan®-Fludara® Highly Effective for Extranodal MALT B-cell Lymphomas(11/9/2009) Researchers from Spain have reported that Rituxan® (rituximab) and Fludara® (fludarabine) produces complete remissions in 90% of newly diagnosed patients with extranodal marginal-zone lymphomas of the mucosal-associated lymphoid tissue (MALT) type. The details of this study were published in the November 15, 2009 issue of Cancer.
Cytarabine Improves Results of High-dose Methotrexate in Patients with Primary CNS Lymphoma(10/9/2009) Researchers involved in a multicenter European-South American study have reported that the addition of high-dose cytarabine to high-dose methotrexate improves the response rate in patients with primary central nervous system lymphoma (PCNSL). The details of this study were published early online on September 20, 2009 in The Lancet.
Zevalin® Active for Treatment of Extranodal Marginal-zone Lymphoma(10/6/2009) Researchers from Italy have reported that patients with relapsed or refractory extranodal marginal-zone lymphoma have a high response rate following treatment with Zevalin® (90Yttrium-ibritumomab tiuxetan). The details of this study were presented at the Joint ECCO 15 – 34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
High Time Costs for Informal Care Givers of Cancer Patients(9/10/2009) Researchers from the National Cancer Institute (NCI) have reported that the time spent by informal caregivers is significant and an important component in the overall burden of cancer care. The details of this study appeared in the September 4, 2009 issue of Cancer.
Mozobil® and Neupogen® Superior to Neupogen® Alone for Harvesting Peripheral Blood Stem Cells(9/9/2009) Researchers involved in a Phase III randomized multicenter U.S. trial have reported that Mozobil® (plerixor, AMD3100) plus Neupogen® (filgrastim) facilitated the collection of optimal numbers of peripheral blood CD34+ cells from a higher portion of patients with non-Hodgkin’s lymphoma (NHL) than Neupogen alone. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on August 31, 2009.
Elderly Patients with Bulky NHL Who Achieve a PR to Chemotherapy May Benefit from Local Radiotherapy(11/17/2009) Researchers from Germany have reported that elderly patients with aggressive non-Hodgkin’s lymphoma (NHL) with bulky disease who achieve a partial response (PR) after chemotherapy may benefit from local radiotherapy. The details of this study were presented at the 2009 meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO) in the first week of November.
High Time Costs for Informal Care Givers of Cancer Patients(9/10/2009) Researchers from the National Cancer Institute (NCI) have reported that the time spent by informal caregivers is significant and an important component in the overall burden of cancer care. The details of this study appeared in the September 4, 2009 issue of Cancer.
Mozobil® and Neupogen® Superior to Neupogen® Alone for Harvesting Peripheral Blood Stem Cells(9/9/2009) Researchers involved in a Phase III randomized multicenter U.S. trial have reported that Mozobil® (plerixor, AMD3100) plus Neupogen® (filgrastim) facilitated the collection of optimal numbers of peripheral blood CD34+ cells from a higher portion of patients with non-Hodgkin’s lymphoma (NHL) than Neupogen alone. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on August 31, 2009.
Phase III Trial of Expanded Umbilical Cord Blood (StemEx®) for Treatment of Hematologic Malignancies Announced(6/17/2009) Researchers from the University of Pittsburgh and Gamida Cell announced that the University of Pittsburgh would be participating in an international multicenter Phase III study of StemEx® for the treatment of hematologic malignancies. There are currently 15 U.S. centers and 11 centers in Europe and Israel participating in this study. This study is classified as a Phase III study but, because it is not randomized, patients will be compared to matched historical controls.
Epratuzumab and Rituxan® with CHOP 21 Highly Effective in Patients with Diffuse Large B-cell Lymphoma(6/1/2009) Researchers involved in a Northcentral Cancer Treatment Group trial N0489 Phase II trial have reported that combining epratuzumab and Rituxan® (rituximab) with CHOP 21 is feasible and promising for the treatment of newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). The details of this study were presented on May 28 at the 2009 meeting of the American Society of Clinical Oncology in Orlando, Florida.
High Time Costs for Informal Care Givers of Cancer Patients(9/10/2009) Researchers from the National Cancer Institute (NCI) have reported that the time spent by informal caregivers is significant and an important component in the overall burden of cancer care. The details of this study appeared in the September 4, 2009 issue of Cancer.
Mozobil® and Neupogen® Superior to Neupogen® Alone for Harvesting Peripheral Blood Stem Cells(9/9/2009) Researchers involved in a Phase III randomized multicenter U.S. trial have reported that Mozobil® (plerixor, AMD3100) plus Neupogen® (filgrastim) facilitated the collection of optimal numbers of peripheral blood CD34+ cells from a higher portion of patients with non-Hodgkin’s lymphoma (NHL) than Neupogen alone. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on August 31, 2009.
Trisenox®, Interferon-alfa, and Retrovir® Effective for Adult T-cell Leukemia/Lymphoma(5/8/2009) Researchers from Iran and France have reported that a regimen of Trisenox® (arsenic trioxide), interferon-alfa, and Retrovir® (zidovudine) is highly effective in patients with adult T-cell lymphoma/leukemia (ATL). The details of this study appeared in an early online publication in Blood on May 1, 2009.
The American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia(2/2/2009) At the 2008 meeting of the American Society of Clinical Oncology (ASCO), there were more than 100 abstracts devoted to the treatment of lymphoma. There is increasing evidence that survival of patients with lymphoma and chronic lymphocytic leukemia (CLL) is steadily increasing. New drugs are being developed at a reasonable rate, which creates the question of how best to incorporate all the available drugs in an optimal manner. Additionally, there appears to be significant progress in reduced-intensity allogeneic stem cell transplants for low-grade lymphomas.
Xcytrin® (Motexafin Gadolinium) May Improve Results of Zevalin® for Treatment of Refractory NHL(10/26/2009) Researchers from the Robert H Lurie Comprehensive Cancer Center have reported that the addition of Xcytrin® to Zevalin® ([90Y] ibritumomab tiuxetan) may improve treatment of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL). The details of this study appeared early online in Clinical Cancer Research.
Veltuzumab Effective for CD20+ Non-Hodgkin’s Lymphoma Refractory to Rituxan®(7/13/2009) Researchers involved in a multicenter U.S. trial have reported that the humanized monoclonal antibody veltuzumab has significant activity in patients with CD20+ non-Hodgkin’s lymphoma (NHL) who had previously failed Rituxan® (rituximab). The details of this Phase I/II study appeared in the July 10, 2009 issue of the Journal of Clinical Oncology.
Phase III Trial of Expanded Umbilical Cord Blood (StemEx®) for Treatment of Hematologic Malignancies Announced(6/17/2009) Researchers from the University of Pittsburgh and Gamida Cell announced that the University of Pittsburgh would be participating in an international multicenter Phase III study of StemEx® for the treatment of hematologic malignancies. There are currently 15 U.S. centers and 11 centers in Europe and Israel participating in this study. This study is classified as a Phase III study but, because it is not randomized, patients will be compared to matched historical controls.
Reduced-intensity Allogeneic Stem Cell Transplants Effective for Relapsed DLBCL(1/20/2009) Researchers from the UK have reported a 48% progression-free survival in patients with relapsed diffuse large B-cell lymphoma (DLBCL) following reduced-intensity allogeneic stem cell transplantation. The details of this Phase II study appeared in the January 20, 2009 issue of the Journal of Clinical Oncology.
Gemzar® Effective for Peripheral T-cell Lymphomas and Mycosis Fungoides(11/9/2009) Researchers from Italy have reported that Gemzar® (gemcitabine) is effective single-agent therapy for previously treated patients with peripheral T-cell lymphoma (PTCL) and mycosis fungoides (MF). The details of this study appeared in an early online publication in the Annals of Oncology on November 3, 2009.
Folotyn™: First Drug Approved by the U.S. FDA for Treatment of Peripheral T-Cell Lymphoma(10/6/2009) On September 25, 2009 the U.S. Food and Drug Administration approved Folotyn™ (pralatrexate) for the treatment of peripheral T-cell lymphoma (PTCL). This is the first drug specifically approved for the treatment of PTCL. The basis for this approval was the international PROPEL (Pralatrexate in patients with Relapsed OR refractory PEripheral T-cell Lymphoma) trial. An update of the PROPEL trial was presented at the Joint ECCO 16 -34th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.
Allogeneic Stem Cell Transplantation Effective for Angioimmunoblastic T-cell Lymphoma(7/24/2009) Researchers affiliated with the European Working Party of the European Group for Blood and Marrow Transplantation have reported that allogeneic stem cell transplantation results in long-term disease-free survival in approximately 50% of patients with angioimmunoblastic T-cell lymphoma (AITL). The details of this study appeared in an early online publication on July 20, 2009 in the Journal of Clinical Oncology.
The American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia(2/2/2009) At the 2008 meeting of the American Society of Clinical Oncology (ASCO), there were more than 100 abstracts devoted to the treatment of lymphoma. There is increasing evidence that survival of patients with lymphoma and chronic lymphocytic leukemia (CLL) is steadily increasing. New drugs are being developed at a reasonable rate, which creates the question of how best to incorporate all the available drugs in an optimal manner. Additionally, there appears to be significant progress in reduced-intensity allogeneic stem cell transplants for low-grade lymphomas.
Romidepsin Active for Treatment of Refractory Cutaneous T-Cell Lymphoma(12/17/2008) Researchers involved in an international multicenter trial have reported that romidepsin is effective for the treatment of patients with cutaneous T-cell lymphoma (CTCL). The results of this study were presented at the 50th annual meeting of the American Society of Hematology in San Francisco on December 8, 2008.
Torisel® Active in Relapsed or Refractory Mantle Cell Lymphoma(10/21/2009) Researchers from Germany have reported that Torisel® (temsirolimus) improves progression-free survival (PFS) in patients with relapsed or refractory mantle cell lymphoma (MCL). The details of this Phase III study were published in the August, 2009 issue of the Journal of Clinical Oncology.
Revlimid® Active for Treating Mantle Cell Lymphoma(4/22/2009) Researchers from the Mayo Clinic have reported that Revlimid® (lenalidomide) has significant activity in patients with refractory mantle cell lymphoma. The details of this study appeared in the May 1, 2009 issue of the British Journal of Haematology.
The American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia(2/2/2009) At the 2008 meeting of the American Society of Clinical Oncology (ASCO), there were more than 100 abstracts devoted to the treatment of lymphoma. There is increasing evidence that survival of patients with lymphoma and chronic lymphocytic leukemia (CLL) is steadily increasing. New drugs are being developed at a reasonable rate, which creates the question of how best to incorporate all the available drugs in an optimal manner. Additionally, there appears to be significant progress in reduced-intensity allogeneic stem cell transplants for low-grade lymphomas.
Rituxan® and Intensive Chemotherapy Prolongs Remission of Mantle Cell Lymphoma(12/17/2008) Researchers from the M. D. Anderson Cancer Center have reported that R (rituximab)-HyperCVAD alternated with R-MA (methotrexate/cytarabine) improves failure-free survival in patients with newly diagnosed mantle cell lymphoma. The details of this long-term follow-up report were presented at the 50th Annual Meeting of the American Society of Hematology on December 9, 2008 in San Francisco.
Revlimid® Effective for Relapsed or Refractory Non-Hodgkin’s Lymphoma(12/16/2008) Researchers involved in the international Phase II trial, NHL-003, have reported data that confirms the effectiveness of Revlimid® (linalidomide) for the treatment of patients with relapsed or refractory mantle-cell lymphoma and diffuse large B-cell lymphoma. These results were presented at the 50th annual meeting of the American Society of Hematology on December 8, 2008 in San Francisco.
Patient Home
